13th Pharmacovigilance 2017

"Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

27th & 28th September 2017, Holiday Inn Chicago O'Hare, USA

Book now...
Register now to secure your seats
Call +44 2036120886
or
email - info.uk@virtueinsight.com

Key Speakers Include

GERSON PELTZ, Pfizer,
Senior Director - Oncology Safety Risk Lead

MELVA T. COVINGTON, Sanofi,
Senior Director, Head of Field Based Medical Strategy

FATEMEH NOURI. E, FDA,
Postdoctoral Fellow

DEEPA ARORA, Lupin (India),
Vice President - Pharmacovigilance & Global Head- Drug Safety & Risk Management

KHAUDEJA BANO, Abbott,
Senior Medical Director, Medical Affairs

BRUCE DONZANTI, Genentech,
Senior Group Director, Regulatory Pharmacovigilance Policy

BRIAN DREYFUS, Bristol-Myers Squibb,
Director

CARMIT STRAUSS, Amgen,
Global Risk Management Scientist / Safety Management – GPS

BEN LOCWIN, Healthcare Science Advisors,
President

REEMA MEHTA, Pfizer,
Senior Director, Head of Risk Management Center of Excellence

ESTHER DE LA CUESTA, Takeda Pharmaceuticals,
Senior Medical Director, Pharmacovigilance

ANKA G. EHRHARDT, Bristol-Myers Squibb,
Director Clinical Cytometry, Biomarker Technologies, ECTR

BARBARA DA SILVA-TILLMANN, Abbvie,
Senior Medical Director

GEORGE VAN BAELEN, Shire,
Head Pharmacovigilance Latin America & Carribean

SHELLY GOODMAN, Portola Pharmaceuticals,
Head, Global Pharmacovigilance

PHILLIP EICHORN, Pfizer,
Senior Director (Worldwide Safety and Regulatory)

SHEETAL KHEDKAR, Sarah Cannon Development Innovations,
Senior Director, Regulatory Science

ROBERT S. WALSH, Walsh Medical Consulting,
Consultant

Plus many more COMING SOON.....

Special reasons to Attend

- Pharmacovigilance in the US: where are we heading?
- Updates - Legislation, policies, systems, technology, communication strategies
- Challenges and Opportunities to optimize the overall PV ecosystem
- Office of Surveillance and Epidemiology (OSE) within CDER.
- Postmarketing safety monitoring within OSE
- Pharmacovigilance and healthcare system
- Revised GVP guidance on signal management
- Data quality management and analysis
- Future of outsourced phase I, II and III trials
- Strategies to improve clinical trials and PV
- Balance in relationships: Sponsor – Site – CRO & Patients
- Safety Reporting in Licensing Agreements
- Global integration of pharmacovigilance services - Latin America and the Caribbean
- Patient centric approach to help improve patient safety
- PV Audit & inspections - preparation, implementation and lessons to be learnt
- Outsourcing Vs In-House
- The effect of Brexit on Pharmacovigilance
- PV - Current regulations and guidelines – USA, EU & RoW
- The developing regulatory framework in advanced and developing markets
- Be part of a major networking opportunity

Learn, Partner, Innovate, Suceed

Virtue Insight

13th Pharmacovigilance 2017
27th & 28th September 2017, Holiday Inn Chicago O'Hare, USA

Dear Colleagues,

Global Pharmacovigilance Market expected to Reach US$6.1 bn by 2020 expanding at a CAGR of 14.2% from 2015 to 2020 and also expected to reach a market size of $8.23 billion by 2022.

Medicinal products changed the way in which diseases are achieved and controlled in the current era of medical technology. Regardless of the benefits, Adverse Drug Reactions (ADRs) continue to rise leading to illness, disability and even death of the patients. Globally, ADRs are one of the leading causes of mortality. Monitoring and evaluation of drug safety becomes vital in order to enhance public health, which requires a (PV) system in place. Globalization and free trade explosion have changed the way individuals today access medicinal products. Therefore, effective collaboration is required between pharmaceutical organizations and the key pv players in order to minimize the risks associated with the use of medicines. By 2020, the size of the global pharmaceutical market is anticipated to grow to USD 1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey. The rapid induction in the market throws up the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base. Along with clinical trials Bioavailability and bioequivalence studies also plays major role in clinical research. The global market for Biopharmaceuticsin 2013 was $305.1 million, which is expected to reach about $326.3 million by year-end 2014. The projected PAT instrumentation market is expected to be valued at around $450.6 million by 2019 at a compound annual growth rate (CAGR) of 6.7% for the period of 2014 to 2019

13th Annual Pharmacovigilance 2017 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organizations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pv requirements, and to improve their organizations' compliance with pv requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting Pv development. What does the future hold for pv? Find out at our conference on opportunities and activities shaping pv to 2020 with respect to regulations, technologies and services. Learn and know on what are drug producers and service providers doing? What regulations and technologies influence the current pv field? You can also discover at 13th Pharmacovigilance 2017 on spending forecasts for pv (US, the EU and Asia).

It gives me great pleasure in welcoming all of you to the Virtue Insight's 13th Pharmacovigilance 2017. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.

Regards,

Fen Castro
Head Productions
Virtue Insight

Exhibitor

eVe Drug

Supported By

EXPLARA Eventbrite

pharmaphorum bringing healthcare together

GoingToMeet Where Business and People Converge

Conference locate.com

Organized By

Virtue Insight

13th Pharmacovigilance 2017
27th & 28th September 2017, Holiday Inn Chicago O'Hare, USA

SPECIAL REASONS TO ATTEND

- Establishing and streamlining pharmacovigilance in the US: where are we heading?
- Updates towards of legislation, policies, systems, technology, communication strategies and best practice in PV
- Analyzing the Challenges and Opportunities to optimize the overall PV ecosystem
- Why does pharmacovigilance sometimes fail and where could the fault lie?
- Updates from the Office of Surveillance and Epidemiology (OSE) within CDER.
- Postmarketing safety monitoring within OSE
- Pharmacovigilance and healthcare system
- Revised GVP guidance on signal management – how to implement?
- Updates to PSUR, PBRERs, DSUR, PASS
- Review the various data sources available in post-marketing setting and their pros & cons
- Good Clinical Practices and Good Pharmacovigilance practices
- Future of outsourced phase I, II and III trials and post-marketing studies, inc. pharmacovigilance
- Emerging technologies to efficiently collect, store and analyze data in a comprehensive data management system
- Strategies to improve clinical trials and PV
- Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
- Patient centric approach to help improve patient safety
- Outsourcing activities - How to set it right?
- PV Audit & inspections - preparation, implementation and lessons to be learnt
- Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
- Outsourcing Vs In-House
- The effect of Brexit on Pharmacovigilance
- Current regulations and guidelines - USA and EU PV
- The developing regulatory framework in advanced and developing markets
- Accelerating new medicine introduction in developing world & overcoming challenges
- Be part of a major networking opportunity

AN EVENT TO VOW

13th Pharmacovigilance 2017 – "Uniting "Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our **dedicated networking drinks time, meet the leading international vendors** showcasing the products of tomorrow in the co-located exhibition. **Expand your knowledge** of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway. Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.

WHY EXHIBIT?

Make Sales
Debut new products
Profile your brand
Meet new business partners
Develop key relationships
Educate pharma and biotech companies

WHO WILL YOU MEET

CEO's, CTO's, CIO's, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:

Pharmacovigilance, Pharmacoepidemiology, Pharmacogenomics, Drug/Product Safety, Drug Development, Information and Clinical Data Management, Clinical Pharmacology, Clinical Safety, Periodical safety update Reports, Risk Management, Research & Development, Quality Assurance, Patient Safety, Signal Detection, Safety Surveillance, Outcomes Research, Data Analysis, Epidemiology, Medical Affairs, Regulatory Affairs and Compliance, Information technology, Sales and Marketing

13th Pharmacovigilance 2017
27th & 28th September 2017, Holiday Inn Chicago O'Hare, USA

DAY ONE – 27th SEPTEMBER 2017

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:30 – Chairperson opening remarks

ROBERT S. WALSH, Consultant, **Walsh Medical Consulting**

MARKET TRENDS & WAY FORWARD

09:40 – Morning Keynote Address 1 - Strengthening and rationalizing Pharmacovigilance in the US: where are we heading?

- Updates from the Office of Surveillance and Epidemiology (OSE) within CDER.
- Postmarketing safety monitoring
- within OSE
- An overview of pharmacovigilance, pharmacoepidemiology, pharmaceutical risk management, and medication error prevention.
- Does the shift towards emerging markets pose a risk to drug safety and biased data reports?

QUALITY - SAFETY

10:20 – Morning Keynote Address 2 – Safety Reporting in Licensing Agreements

DEEPA ARORA, Vice President - Pharmacovigilance & Global Head- Drug Safety & Risk Management, **Lupin (India)**

10:50 – Morning Coffee/Tea & Discussion

11:10 – Decipher the final Post-Market Safety Reporting (PMSR) Rule for combination products

- Products – definition
- What does the final rule expect? Key concepts
- Case-scenario of a simple combination product

KHAUDEJA BANO, Senior Medical Director, Medical Affairs, **Abbott**

CHALLENGES & OPPORTUNITIES

11:40 – Keynote Panel Discussion: Challenges and Opportunities – Optimize the overall PV ecosystem for maximum benefit

- Staying ahead in the race - Update on PV in EU, USA & RoW - Current trends for PV, and new and future guidelines
- Globalization of Pharmacovigilance
- Pharmacovigilance - The effect of Brexit
- Comparison of Pharmacovigilance in the US, Latin America, Asia, Caribbean and Europe
- How to create a proactive drug safety culture?
- What can we learn from successful experiences from RoW?
- Where is the market heading and what needs to be done?
- Brexit and the impact on Pharmacovigilance

Moderator:

ROBERT S. WALSH, Consultant, **Walsh Medical Consulting**

Panellists:

FATEMEH NOURI. E, Postdoctoral Fellow, **FDA**

KHAUDEJA BANO, Senior Medical Director, Medical Affairs, **Abbott**

REEMA MEHTA, Senior Director, Head of Risk Management Center of Excellence, **Pfizer**

12:20 – Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

---

12:40 – Networking luncheon

13:40 – Global integration of pharmacovigilance services - Latin America and the Caribbean

GEORGE VAN BAELEN, Head Pharmacovigilance Latin America & Carribean, **Shire**

PRE-CLINICAL & CLINICAL TRAILS

14:10 – Pharmacovigilance through a Products Life Cycle

- Building the continuum of pharmacovigilance across premarketing and post-marketing
  - Challenges in clinical trials
  - Challenges postapproval
- Targeted event collection
- Strengthening the link between a drug and its related adverse events from pre-clinical to post-marketing
- Future of outsourced phase I, II and III trials and postmarketing studies, inc. pharmacovigilance

14:40 – Topic TBC

15:10 – Afternoon Tea/Coffee

13th Pharmacovigilance 2017
27th & 28th September 2017, Holiday Inn Chicago O'Hare, USA

IMPACT OF TECHNOLOGY

15:30 – IT business opportunities in Pharmacovigilance

- Emerging technologies to efficiently collect, store and analyze data in a comprehensive data management system
- Opportunities for PV Software Services companies
- Cloud – Big data – Analytics
- Use of mobile technologies and social media in pharmacovigilance

16:00 – Data Quality Management and analysis

- Describe electronic case reporting to Adverse Event Reporting System
- Explain data quality issues encountered with electronic ICSR submissions
- Discuss data quality issues related to suspect product identification, using examples
- Discuss data quality issues related to MedDRA coding for adverse events and medication errors, using examples
- Periodic Benefit-Risk Evaluation Report

OUTSOURCING

16:30 – Outsourcing Vs In-House

- Preliminary set up steps – what are all to be looked into?
- Moving forward – what are the deals that are to be communicated
- Steps to be taken in order to maintain efficacy and quality
- Monitoring constantly and effects of proper communication
- Benefits and risks of managing a pharmacovigilance-outsourced organization

17:00 – Chairperson's closing remarks and end of conference

ROBERT S. WALSH, Consultant, **Walsh Medical Consulting**

17:10 - 18:10 - Networking Drinks - Take your discussions further & build new relationships in a relaxed & informal setting

FOR DELEGATE REGISTRATIONS:-

Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments & enable them to network with the industry key personnel.

Delegate Registration - delegate.uk@virtueinsight.com

13th Pharmacovigilance 2017
27th & 28th September 2017, Holiday Inn Chicago O'Hare, USA

DAY TWO - 28th SEPTEMBER 2017

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues.

09:30 – Chairperson opening remarks

BEN LOCWIN, President, **Healthcare Science Advisors**

SIGNAL DETECTION

09:40 – Morning Keynote Address 1 – Signal detection & management

- Evolving developments in pharmacovigilance
- What are the new technologies to determine the risk in PV signal detection?
- Aligning expectations between industry and regulators on signal detection and investigation
- How to monitor safety in blinded clinical trials
- Statistical approaches to looking at blinded data and detecting signals
- Signals validated by MAHs – procedural options
- Signal Detection:
- Innovations and challenges

ESTHER DE LA CUESTA, Senior Medical Director, Pharmacovigilance, **Takeda Pharmaceuticals**

BUSINESS MODELS

10:10 – Solution Provider Presentation

For sponsorship opportunities please contact info.uk@virtueinsight.com

10:30 – Recent update in GVP module V

11:00 – Morning Coffee/Tea & Discussion

SPONSOR - SITE - CRO - PATIENTS

11:20 – Keynote Panel Discussion – Maintaining proper communicaton between - Sponsor – Site – CRO & Patients

- Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
- Directions or recommendations on reporting and unblinding clinical trial safety reports to authorities, investigators, and IRBs
- Achieving harmonisation – How are we working together to improve drug safety
- Patients involvement for a better PV knowledge - Patient support programs
- Customer engagement programs - add value and support pharmacovigilance practices
- Benefit-risk evaluation: the past, the present and the future
- Pharmacovigilance and risk management planning

Moderator:

BEN LOCWIN, President, **Healthcare Science Advisors**

Panellists:

MELVA T. COVINGTON, Senior Director, Head of Field Based Medical Strategy, **Sanofi**

GERSON PELTZ, Senior Director - Oncology Safety Risk Lead, **Pfizer**

ANKA G. EHRHARDT, Director Clinical Cytometry, Biomarker Technologies, ECTR, **Bristol-Myers Squibb**

BARBARA DA SILVA-TILLMANN, Senior Medical Director, **Abbvie**

SHEETAL KHEDKAR, Senior Director, Regulatory Science, **Sarah Cannon Development Innovations**

PV - RISK MANAGEMENT & PLANNING

12:00 – How to incorporate the patient voice and develop effective risk minimization tools

CARMIT STRAUSS, Global Risk Management Scientist / Safety Management – GPS, **Amgen**

12:30 – Networking luncheon

13:40 – Topic TBC

SHELLY GOODMAN, Head, Global Pharmacovigilance, **Portola Pharmaceuticals**

14:10 – Social media and pharmacovigilance

- How does social media fit into the standard pharmacovigilance workflow
- How does social media compare to FAERS and administrative claims
- What are some other areas of potential for social media (e.g. drug abuse)

BRIAN DREYFUS, Director, **Bristol-Myers Squibb**

14:40 – Achieving harmonisation – How are we working together

- How are we to work together to improve drug safety
- Patients involvement for a better PV knowledge –
- Patient support programs

15:10 – Afternoon Tea/Coffee

PV AUDIT & INSPECTIONS

15:30 – PV Audit & Inspections - Preparation, implementation and lessons to be learnt

- Major and a vital role - Monitoring PV compliance
- PV Inspection readiness: What to expect? How ready can we be?
- PV Compliance: PV is at the Center but cannot do it alone. How to mobilize internal and external stakeholders?
- Risk based selection criteria for auditing
- Methodologies, scope and oversight
- Relationship to other GxPs

REGULATORY

16:10 – Panel Discussion: The developing regulatory framework

- Keep abreast with the changing regulations of PV - Current PV practices in the EU & US
- Review – USFDA & MHRA
- An industry perspective on global pharmacovigilance regulatory developments and impacts discussed
- Importance to balance between the need for maintaining trial integrity and identifying and alerting on any potential safety issue
- Maturing Markets Regulatory Updates

Moderator:

BEN LOCWIN, President, **Healthcare Science Advisors**

Panellists:

BRUCE DONZANTI, Senior Group Director, Regulatory Pharmacovigilance Policy, **Genentech**

PHILLIP EICHORN, Senior Director (Worldwide Safety and Regulatory), **Pfizer**

16:50 – 17:00 – Chairperson's closing remarks and end of conference

BEN LOCWIN, President, **Healthcare Science Advisors**

13th Pharmacovigilance 2017

FLOOR PLAN - Book your stalls now before they run out !!!



1		5	
2	eVe Drug	6	
3		7	
4		8	

Note :- The floorplan is subject to change at the discretion of the organisers.

SAMPLE LIST OF PAST ATTENDEES

Abbvie - Pharmacovigilance Manager & QPPV
Abbvie - Medical Director Pharmacovigilance & Patient Safety
AbbVie AB - Drug Safety Manager
Actelion Pharmacetuicals - Quality, Compliance & Regulatory Manager
ADAMAS Consulting - Head of GVP Practice
Aegerion Pharmaceuticals - Senior Manager, Drug Safety
Agency - Medical Products & Medical Device - Pharmaceutical Inspector
AKOS - Business Development Manager
Allergan - Global Research and Development Quality
Amgen - Medical Director
Aprova - Business Manager
Aptiv Solutions - Director Business Development
Archimed Medical Communication - Commercial Director
Association of the British Pharmaceutical Industry - Head of Regulatory and Safety Policy
AstraZeneca - VP Patient Safety
AstraZeneca - Director at Patient Safety,
Auden Mckenzie (Pharma Division) - PV Lead & Deputy QPPV
AXESS - Talent Acquisition Manager for PV
Azin Pharma - EU QP PV
Azin Pharma - Deputy of EU QP PV
Azin Pharma - Senior Pharmacovigilance Officer
Barrington James - Sales Manager
Baxter Healthcare - Sr PV Associate
Bayer - Pharmacovigilance Country Head
Biogen Idec - Drug Safety Associate
Bluefish Pharmaceuticals - Deputy QPPV
Boehringer Ingelheim - PVP
Boehringer Ingelheim - Head Strategic Data Analysis, Global Pharmacovigilance
Boots Pharmaceuticals - Head of Quality & Safety
Bristol Myers Squibb - VP International and QPPV EU GPV&E
Bristows - Senior Associate
Business wire - Regional Manager- Business Development
Callisto Consulting - Regulatory Affairs & Drug Safety Officer
Celgene - Drug Safety Specialist
Celgene - Director Medical Reviewer
Celgene - Associate Director
Celgene Europe - Associate Director, Global Risk Management
Celgene Europe - Associate Manager, Drug Safety
CKA Group - Senior Recruitment Consultant
Cmed Clinical Service - Director of Business Development
CSD MR UK - Director of Medical Research
CSL Behring - SVP - Global Quality
Daiichi Sankyo Development - Sr. Scientist
Deloitte Consulting - Sr. Manager
Dingsons - Director
Dr. Ebeling & Assoc. - Senior PV Advisor
Dr. Ebeling & Assoc. - General Manager
Drug Safety Research Unit - Director
DSRU - Principal Research Fellow
Dubai Healthcare City - Senior Executive of Pharmaceutical Services - QID
EGA (European Generic Medicines Association) - Medical Affairs Manager
Egis Pharmaceuticals - Head of Drug Safety Department
Eisai Pharmaceuticals - Sr. VP Regulatory,
Eli Lilly - Consultant - EQAAC
Emas Pharma - Chief Operating Officer
EUDRAC - Assoicate Director
European Regulatory Solutions - Regulatory Affairs Consultant
Foresight Group International AG - Senior Director
Fresenius Kabi - Vigilance Officer
Frontline Pharma Consulting - Chief Medical Officer
GCP QA Auditing and Consulting Inc - Compliance Auditor
Genpact - VP
Genpact - Assistant VP
German Pharmaceutical Industry Association - Head of Pharmacovigilance
Gilead Sciences International - Senior Manager
Ginsana SA - PV Specialist
Grunenthal GmbH - Quality Assurance Manager
GW Pharmaceuticals - PV Manager
GW Pharmaceuticals - Senior PV Compliance Specialist
GW Pharmaceuticals - Senior Pharmacovigilance Associate
Healthcare Data - Consultant Expert
Hikma Pharmaceuticals - Medical Affairs Specialist
Hospices Civils de Lyon - Head of Vigilance Unit
Hydrogen Group - Consultant - Regulatory, Quality
IMS Health - General Manager, Social Media
IMS Health - Director, Marketing - Social Media Solutions
IMS Health - Principal
Indivior Pharma - Pharmacovigilance Quality Manager
Inventiv Health Clinical - Sr Director, Glb Safety & Pharmacovigilance
IPPro Lifesciences - Marketing Manager
Janssen Infectious Diseases - Associate Director
JensonR+ Limited - Senior Pharmacovigilance Officer
Johnson & Johnson - Senior Director, Regulatory Compliance R&D at Janssen
Kemri - Pharmacist
Keyrus Biopharma - Drug Safety Scientist
Keyrus Biopharma - Quality Assurance Manager
Kuwait National Petrolium Company - Pharmacist
Lambda Therapeutic Research - Chief Operating Officer
Lambda Therapeutic Research - Director of Business Development (Pharmacovigilance),
LEO Pharma A/S - Manager
LINK Medical Research AS - Head of Pharmacovigilance
Lupin - Global Head, Drug Safety & Risk Management
Markets&Markets - Sales & Marketing Professional
McCrowley and Hughes - Partner
Medac UK - Medicines Information Specialist
Medicorum - Medical Director
MedImmune - Associate Director Patient Safety, PV Operations
MedImmune - Medical Director
Merck - Pharmacovigilance Country Lead
Merck Sharp & Dohme - EU QPPV Support Physician
MHRA - Statistician, Epidemiologist Clinical Practice Research Datalink
Microtracers Inc - Marketing Manager
MSD - Associate Director, PV Compliance
Mundipharma Research - PVG Physician
Myriad-RBM - Director of Business Development
Nanokinetik - CEO
Nanokinetik - Product Manager
Navitas Life Sciences - Marketing Consultant
NDA - Principal Consultant, Pharmacovigilance & Drug Safety
Nelsons - Director of External Regulatory Affairs
Nicovations - CMO & Director of Compliance
Nicovations - QP
Nicovations - Regulatory Affairs Manager
Norweigen Medicines Agency - Medical Director
Novartis - Deputy EU QPPV
Novartis Consumer Health - Sr Drug Safety Advisor
Novartis Pharma S.A.S. - Pharmacovigilance Expert
Novo Nordisk - Sr Director, EU Regulatory Advocacy
Olexacon - Managing Director
Oracle Corporation - Principal Product Strategy Manager
ORION Clinical Services - Head of Pharmacovigilance
ORION Clinical Services - Medical Director
Orion Pharma - Drug Safety Manager
Orphan Europe - Associate Director
Otsuka Europe Development & Commericalisation - EU QPPV
Oviya MedSafe - Managing Director & CEO
OXON Epidemiology - Director of Risk Management Epidemiology
Panacea - QPPV
Parexel - Director, Patient Safety Services
PCS Pharmacovigilance LTD - Director
Pfizer - Director, Safety and Risk Management,
Pfizer - Senior Director (Worldwide Safety and Regulatory)
Pharma International Company - Pharmacovigilance Manager/QPPV
Pharma Voice - Project Coordinator
Pharmacists Council of Nigeria - Deputy Director,
Pharmacosmos - Head of Drug Safety
Pharmaphorum - Managing Editor
PharSafer - Director
Pierre Fabre Medicament - Head of Corporate Vigilances Division

SAMPLE LIST OF PAST ATTENDEES

Piramal Healthcare - QA Officer
Pope Woodhead - Deputy Managing Director
Povey Consultancy - Director
PRA Health Sciences - Senior Director Drug Safety Center
Prism Ideas - CEO
ProductLife - Business Development Manager
ProductLife - PV Operations Manager
Roche - Head EU Compliance
Roche Pharmaceuticals - Drug Safety Associate & LSR backup
Roche Pharmaceuticals - QU & DRA Pharmacist
Roche Products - Patient Safety Optimisation Leader
Sanjeevani Pharma - Director
Sanofi - Senior Pharmacovigilance Officer
Sanofi - QPPV, Head of QPPV Office and Pharmacovigilance Policy
Sanofi-Aventis (Suisse) SA - Affiliate Pharmacovigilance Head
Shionogi - VP Pharmacovigilance
Sidley Austin - Associate
ST. JAMES'S PLACE - Founder Member & Associate Partner
Stallergenes - VP Corporate Pharmacovigilance
Sticares Interact - Clinical Research Physician
Sun Pharma - EU-QPPV - Global Pharmacovigilance
Symogen - Director and QPPV, PV and Pharmacoepidemiology
Symogen - Director
Takeda - Associate Medical Direcotr, Global Medical Safety
Takeda Oncology Company - Oncology Physician & EU Region Medical Advisor - PV Millennium
Takeda Pharmaceuticals - Senior Director
Takeda Pharmaceuticals - Global Director, PV & EU Region Medical Advisor - Lead Oncology Portfolio
Takeda Pharmaceuticals - EU-QPPV and Head Established products
TauRx Therapeutics - Gobal Project Lead
Teofarma S.r.l. - Pharmacovigilance Assistant
Teofarma S.r.l. - QPPV
The Medicines Company - Vice President - EU QPPV
Transcrip Partners LLP - Partner
TruTag Technologies - Director of Business Development -Pharmaceuticals
UBC - Associate Director, Pharmacovigilance
UBC - Executive Director, Global Pharmacovigilance
UCB Celltech - Safety Lead - CNS pipeline
United Biosource - Senior Director Risk Management
United BioSource - CorporationSenior Safety Scientist
United BioSource - CorporationSafety Physician
United BioSource - CorporationSafety Scientist
United BioSource - CorporationSenior Safety
University of Hertfordshire - Senior Lecturer, Pharmacovigilance
Vetmedico bvba - Managing Director
Voisin Consulting Life Sciences - EU QPPV
Wainwright associates - Head of Medical Affairs
Waymade Healthcare - Qualified Person
Weifa AS - Medical Advisor/ QP Pharmacovigilance
Weifa AS - Medical Director
World Customs Organization - IPM Private Sector – Senior Manager
Zigzag Associates - Managing Director, Global Client Services
Zigzag Associates - Senior Director of QA, Pharmacovigilance
Zigzag Associates - Senior QA Manager
4C Pharma Solutions LLC - Chief Operating Officer
A Nelson & Co - Director of External Regulatory Affairs
AB Cube - Business Development Manager
AB Cube - Sales Director
Abbvie - Senior Medical Director, Medical Device Safety Head
AbbVie AG - Senior Manager Pharmacovigilance & Medical Information
Alexion Pharmaceuticals - Associate Director of Global Security
Allergopharma GmbH - Drug Safety Manager - Allergy Business
Amgen - Global Safety Manager, EU QPPV Office
ApoPharma Inc - Director, Quality Assurance
Astellas Pharma Europe B.V - Associate Strategy & Planning Director
Astellas Pharma Europe B.V - Medical Safety Director
Astellas Pharma Europe BV - Medical Director
AstraZeneca - PV Program Lead, Science Unit QA
Axcess - Talent Acquisition Manager
Azierta Contract Scientific Support Consulting S.L - Head of Pharmacovigilance & Safety
Bavarian Nordic - Director Pharmacovigilance, QPPV
Besins Healthcare Pharma Services - Head of Global Pharmacovigilance & EU QPPV
Bioclinica - Global VP Business Development
Bioclinica - Director Drug Safety & Risk Management
Bioclinica - Director Business Development
BIOFARMA - Qualified Person Responsible for Pharmacovigilance (QPPV) LLC
Biogen - Senior Medical Director Safety and Benefit Risk Management - EU-QPPV Deputy
Bluefish Pharmaceuticals - QPPV, Head of Pharmacovigilance,
Boehringer Ingelheim - Head Strategic Data Analysis, Global Pharmacovigilance
Brinker Pharma GmbH - PV Manager
Bristol-Myers Squibb - Director of International Operations & Pharmacovigilance Intelligence
Bristows - Senior Associate
Celgene Europe - Drug Safety Specialists
Celgene Europe - Associate Director, Regional Affiliate Operations Lead
Celgene Europe - Associate Director Medical Review
Cheplapharm Arzneimittel GmbH - Pharmacovigilance Manager
Covance CAPS - Manager, Covance PV&DSS
Covance CAPS - Senior DSA, Covance PV&DSS
Covance CAPS - Drug Safety Project Manager
Dawson & Co Consulting - Pharmacovigilance Consultant
Deloitte - Director
Genentech - Principal Program Manager
HighPoint Solutions - Senior Director, Sales and R&D Europe
HighPoint Solutions - VP, Pharmacovigilance Practice
HighPoint Solutions - R&D Practice Director, Member of EU ISO IDMP Task Force
Indegene - Senior Manager Scientific Writing-Medical Solutions
Indegene - Associate Manager-Business Development
Jenson R+ - Senior PV Officer and dQPPV
Jenson R+ - PV Officer
Jenson R+ - Regulatory and PV Officer
Johnson & Johnson - Consultant, Medical Advisor, Pharmacovigilance
Johnson and Johnson - Medical Director PV system Oversight QPPV Office
Kantar Health - Global Compliance and Quality Director
Kinapse - VP Head of Pharmacovigilance Advisory
LG Life Sciences - Pharmacovigilance
Lindeq Bulgaria JSC - Founder
Lupin - Vice President- Pharmacovigilance & Global Head- Drug Safety & Risk Management
Merck Serono - Head Global Drug Safety
Ministry of Agriculture, Livestock and Supply – MAPA , BRAZIL - Officer
NDA Regulatory Science - Senior Consultant
Novartis - Therapy Area Safety Lead, Ophthalmology
Otsuka Novel Products GmbH - Medical Affairs Specialist
Otsuka Novel Products GmbH - Drug Safety Manager
Otsuka Novel Products GmbH - Senior Manager Drug Safety
OXON Epidemiology - Clinical Epidemiologist & Head
Panacea Pharma Projects - Head of Quality
Premier Research Group - Global Head of Pharmacovigilance and Device Safety
Reckitt Benckiser - Senior Global Vigilance Manager / QPPV
Sanofi - Head of Pharmacovigilance - UK & Ireland
Seqirus - Regional Head of Medical Affairs- Europe and ME
Smith & Nephew Medical - Senior Pharmacovigilance Specialist
Smith & Nephew Medical - Director, Post Market Surveillance
Takeda Pharmaceuticals - Global Director, Pharmacovigilance & EU Region Medical Advisor - Lead Oncology Portfolio
TranScrip - Senior Partner
UCB Pharma - Associate Director, Patient Safety
UCB Pharma - Head, Safety analysis and writing
UCB Pharma - Safety Writing Scientist
University Hospitals of Geneva - Adjunct pharmacist
Vifor Pharma - Head Medical & Clinical Drug Safety
Voisin Consulting Life Sciences - Vice President, Disruptive Biologics
ZEINCRO SA - Head Pharmacovigilance & Safety Department
ZEINCRO SA - Senior Safety Officer

13th Pharmacovigilance 2017

27th & 28th September 2017

Registration Form

For Multiple Bookings - Photocopy this form and send it to delegate.uk@virtueinsight.com; Tel:+44 2036120886

Delegate Details:

Title Mr ☐ Mrs ☐ Ms ☐ Dr ☐

First Name

Surname

Company

Position

Address

Postcode

Telephone

Fax

Email

How to Pay
(Choose one of the following payment options)

RESERVATION PRICING:

Early Bird - £900 per delegate (Valid From 5th June 2017 - 6th August 2017) ☐

Standard Rate - £1100 per delegate (Valid From 7th August 2017) ☐

PAYMENT:

Please send me invoice ☐

I enclose a cheque for £

Please charge my card £

Card Number

Security No

Expiry Date / /

Cardholder's Name

Cardholder's Registered Address

Signature

Our purchase order no.is

Payable to **Virtue Insight Events Ltd**

Card type: Visa ☐ Mastercard ☐ Maestro ☐

(Please note that we do not take Amex card payments)

FOR BANK TRANSFER:

Account Name - Virtue Insight Events Ltd **Account Number** - 53278603

Bank Name - Barclays Bank PLC **Sort Code** - 20-84-20

SWIFT Code: BARCGB22 **IBAN Code:** GB36BARC20842053278603

ROUTING Code: 026002574

Special Offer:

3 for 2 Offer

*Only few more seats left

TERMS AND CONDITIONS:

Payment terms: Virtue Insight requires the full amount to be paid before the conference. We may refuse entry to delegates who have not paid their invoice in full.

Cancellations: Delegates and vendor are subject to the following charges and refunds upon withdrawal or cancellation.Between 2-3 month's prior 75% cancellation fee/ 25% refund.Less than 2 months prior to the event Full cancellation fee / No refund.

Substitutions/Name Change: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. This can be done at not extra cost.

Presentation: If you cannot attend the conference, you can still purchase the presentations for £ 400

Indemnity: Virtue Insight reserves the right to make alterations to the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to unforeseen events beyond the control of Virtue Insight. If such a situation arises, we will refund your registration fee and we will try to reschedule the event.

Fee: The conference fee includes lunch, refreshments and conference papers provided on the day. This fee does not include travel or hotel accommodation.

How we will contact you: Virtue Insight's preferred method of communication is by email and phone. Please ensure that you complete the registration form in full so that we can contact you.

UPCOMING CONFERENCES:

- **4th IoT Summit 2017** - **26th July 2017, Bangalore, India**
- **6th Annual Pharma AntiCounterfeiting & Serialisation 2017** - **19th - 20th September 2017, London, UK**
- **13th Pharmacovigilance 2017** - **27th - 28th September 2017, Chicago, USA**
- **14th Pharmacovigilance 2017** - **09th November 2017, Mumbai, India**
- **11th Biosimilars Congregation 2017** - **06th December 2017, Mumbai, India**

For more info on these summits - Kindly contact us at -

Phone - (India) - + 91 44 64536444
Phone - (UK) - + 44 - 2036120886

Email - (India) - info@virtueinsight.com
Email - (UK) - info.uk@virtueinsight.com

Virtue Insight:-

Virtue Insight equips business professionals around the world with the latest indepth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Our motto is to offer our customers the expertise and connections for a profitable business. Our events encompass an optimum chance to gain maximum value in terms of networking and an opportunity to sponsor and exhibit to attract new business alliances.